Worldwide delivery in 2 to 3 business days.Worldwide delivery, 2 to 3 business days after dispatch, tracked and insured. Shipping details
Metabolic, pen
Triple GLP-1/GIP/Glucagon receptor agonist. 39 amino acids. ~6-day half-life. First-in-class metabolic compound.
€139.90
In stock
Subscribe to our newsletter and enjoy 10% off
Retatrutide, 10 mg
€139.90
Also called LY3437943, Triple agonist, GLP-1/GIP/Glucagon agonist, Reta
~6 days in humans (≈144 h, range 108–168 h across phase 1b/2 trials). Long t½ driven by a C20 fatty-diacid albumin-binding linker — not PEGylation. Urva et al., Lancet 2022.
Independent laboratory documentation published by Purita Peptidesfor this product. Each report can be checked on the laboratory's own verification page.
Published by Purita Peptides at puritapeptides.com/certificates; verifiable at janoshik.com/verify Verification key 4FDDMS1MKF6K.
Published by Purita Peptides at puritapeptides.com/certificates; verifiable at janoshik.com/verify Verification key WK2MPR41CZ36.
Published by Purita Peptides at puritapeptides.com/certificates; verifiable at janoshik.com/verify Verification key DDZNN7U3EK7Y.
Retatrutide is a 39-amino-acid linear synthetic peptide developed as the first triple agonist of GLP-1, GIP, and glucagon receptors. The fatty-acid linker enables albumin binding and a ~6-day plasma half-life. It represents one of the most extensively studied next-generation incretin compounds in metabolic research.
Mechanism, reported research areas, literature dose ranges and co-factor studies are on the research page, with sources. Nothing there is a claim about this product.
Read the Retatrutide research overview
Repair
New products, restocks and offers. Your code is shown straight away and emailed to you. Unsubscribe with one click.
Analytics cookies
With your permission we use Google Analytics to see which pages and products are useful. It sets cookies. Our own measurement is cookieless and runs either way. Details in the cookie policy.
